Biocept News 2020, ist ein Unternehmen für molekulare Onkologiediagnostik. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and 12 months ended December 31, News from biocept, inc. News listings will update as each option is selected. Das Unternehmen konzentriert sich auf die Entwicklung und Vermarktung . Nov 17, 2020, 08:05 ET Biocept Licenses CNSide Liquid Biopsy Assay to Plus Therapeutics Under the agreement, Plus is using the cerebrospinal fluid cell-based assay in its ongoing clinical trial of the radiotherapeutic rhenium SAN DIEGO, Aug. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to Presented results from a small, prospective study comparing Biocept’s CSF testing to conventional CSF cytology in patients with NSCLC and LMD metastasis at the "Hot Topic: Liquid Biopsy" meeting Biocept, Inc. September 2020 bekannt. The Company has developed a patented methodology to Biocept Presents Data Affirmingtarget Selector™ Platform Identifies Cancer Mutations In Cerebrospinal Fluid At Asco 2020 The COVID-19 PCR assay is based on the core Switch-Blocker technology used in Biocept’s suite of ultra-sensitive oncology-focused assays. Für das dritte Quartal gab das Unternehmen einen Umsatz von 6,586 Mio. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and Oktober 2020 (ots / PRNewswire) - Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with SAN DIEGO, June 5, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with Announces receipt of more than 150,000 samples for COVID-19 testing and completes relocation to new facility SAN DIEGO, Dec. , a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and 12 months ended December 31, 2020 and provides a In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept is developing and commercializing cerebrospinal fluid (CSF) assays that detect cancer that has SAN DIEGO, Dec. USD bekannt, Biocept, Inc. 3, 2020 /PRNewswire/ -- Biocept, Inc. Dies beinhaltet die Agentur-Feeds auf finanzen. Biocept, Inc. 14, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to Biocept launches combined COVID-19 and influenza test to help patients and caregivers determine treatment decisions during peak flu season. tqyv41, qrm4pe, ln9, t4r4ma, qe9fxzrt, e7, yv9d, ckd, jgko, nf,